BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Pharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Catalyst Pharmaceuticals\, Inc.'s
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04015141-1636@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Fycompa (Perampanel): Phase 2 readout est. (NCT04015141)
DESCRIPTION:Fycompa (Perampanel)\, phase 2\, Epilepsy.\nStudy: A Study to E
 valuate Efficacy and Safety of Perampanel Administered as an Adjunctive Th
 erapy in Pediatric Participants With Childhood Epilepsy\nEstimated primary
  completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/perampanel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04015141
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
